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Background: Due to the increased risk of colorectal cancer, colonoscopic surveillance is recommended for patients with ulcerative and Crohn’s colitis.
Because surveillance intervals differ considerably between the recently updated American Gastroenterological Association (AGA) and British Society of
Gastroenterology (BSG) guidelines, we compared the neoplasia yield and colonoscopic workload of these guidelines.
Methods: Patients with inflammatory bowel disease undergoing surveillance were identified using medical records. Patients were stratified according to
the BSG and AGA guidelines, and corresponding colonoscopic workload was calculated based on the risk factors present during follow-up. The
incidence of colitis-associated neoplasia (CAN), defined as a low-grade dysplasia in flat mucosa or a non–adenoma-like mass, high-grade dysplasia, or
colorectal cancer was compared between the risk groups of either guidelines.
Results: In total, 1018 patients with inflammatory bowel disease who underwent surveillance were identified. Using the AGA surveillance intervals,
64 patients (6%) were assigned to annual and 954 patients (94%) to biannual surveillance, resulting in 541 colonoscopies per year. The yield of CAN was
5.3% and 20.3% in the low- and high-risk groups, respectively (P ¼ 0.02). Using the BSG surveillance intervals, 204 patients received surveillance
annually (20%), 393 patients every 3 years (39%), and 421 patients every 5 years (41%), resulting in 420 colonoscopies per year, which is 22% lower
than the AGA guidelines. The yield of CAN was 3.6%, 6.9%, and 10.8%, for the low-, intermediate-, and high-risk groups, respectively (P ¼ 0.26).
Conclusions: Although the BSG surveillance intervals offer the advantage of a lower colonoscopic workload, the risk stratification of the AGA seems
superior in distinguishing patients at higher risk of CAN.
(Inflamm Bowel Dis 2013;19:2603–2610)
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P atients with longstanding extensive ulcerative colitis (UC) andCrohn’s colitis are at an increased risk of developing colorectal
cancer (CRC).1 For this reason, colonoscopic surveillance has been
advocated, although solid evidence that this indeed prolongs sur-
vival is lacking.2 In 2002, both the American Gastroenterological
Association (AGA) and the British Society of Gastroenterology
(BSG) published their first guidelines describing which patients
should undergo surveillance and how this should be performed.3,4
Although there were some differences regarding the recommended
surveillance intervals between these guidelines, both stated that
regular surveillance with an interval between 1 and 3 years should
be performed after 8 to 10 years of disease duration in case of at
least extensive colitis and after 15 to 20 years in patients with left-
sided disease. Because CRC risk in UC and Crohn’s colitis seems to
be similar for comparable extent and duration, these guidelines are
considered to be applicable to patients with Crohn’s colitis as well.5
Both the BSG and the AGA guidelines were recently
updated to implement new endoscopic techniques and improved
risk stratification.6,7 Although both guidelines still recommend
regular surveillance in all patients with extensive colitis and
now endorse the use of chromoendoscopy, there is no consensus
regarding the intervals between surveillance colonoscopies. The
new BSG guidelines adopt an algorithm based on established risk
factors for colitis-associated CRC to stratify patients in a high-,
intermediate-, and low-risk group with adjusted surveillance inter-
vals. The most striking difference as compared with the previous
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BSG guidelines is that the low-risk group is now recommended to
undergo surveillance every 5 years. The same risk factors are
mentioned in the updated AGA guidelines, but the authors state
that optimal surveillance intervals cannot be clearly defined and
therefore recommend surveillance every 1 to 3 years.
Although longer surveillance intervals offer an advantage
in terms of colonoscopic workload and cost reduction, the
drawback could be a higher number of interval cancers, thereby
reducing its effectiveness. Because a head-to-head comparison of
the updated BSG and AGA guidelines will probably never be
performed, we aimed to establish the guidelines that can identify
patients at risk for neoplasia best. Furthermore, we assessed




All patients with a diagnosis of Crohn’s disease (CD) or
UC from 3 university hospitals and 2 general hospitals were iden-
tified using the Diagnosis Treatment Combinations (DTCs) for
inflammatory bowel disease (IBD). DTCs are based on the Inter-
national Classification of Disease, Ninth Revision, and can be
considered the Dutch version of the Diagnosis Related Groups
that are used in other countries, for example, the United States.8
The medical records and endoscopy reports of all patients
with a DTC code for CD or UC were reviewed to confirm the IBD
diagnosis and to assess whether patients had a valid indication for
surveillance colonoscopy according to the new AGA and BSG
guidelines. Because the new BSG and AGA guidelines do not
concur with regard to the beginning of surveillance (10 and
8 years after the onset of colitis symptoms, respectively), we
considered patients with a disease duration of at least 8 years
eligible for surveillance. Patients with colitis and a concomitant
diagnosis of primary sclerosing cholangitis (PSC) were consid-
ered to have an indication for surveillance immediately after
diagnosis, whereas patients with proctitis or proctosigmoiditis
(patients with UC) or with involvement of ,30% of the colonic
mucosa in case of CD were considered to have no indication for
surveillance and were excluded.
During the study period, all participating centers performed
surveillance in accordance with international guidelines, i.e.,
complete colonic inspection including biopsy sampling of all areas
suspicious for neoplasia with or without the use of chromoendo-
scopy and sampling of 4 random biopsies every 10 cm when
chromoendoscopy was not performed. Standard bowel preparation
consisted of 4 L of polyethylene glycol solution.
All endoscopy reports were reviewed to confirm that
patients underwent at least 1 surveillance colonoscopy. A
surveillance colonoscopy was defined as a procedure with the
clear intention to detect neoplasia (explicitly stated as the
indication for the colonoscopy and/or by taking 4 quadrant
random biopsies every 10 cm). Exclusion criteria were any
previous diagnosis of neoplasia (other than discrete solitary
sessile or pedunculated polyps resembling sporadic adenomas
and containing adenomatous tissue on histology) or (sub)total
colectomy before the first surveillance colonoscopy.
Data Collection
Demographic and clinical data were collected from the
medical records and included date of IBD diagnosis, type of IBD,
disease extent before the start of surveillance, family history of
CRC, medication use, and a concomitant diagnosis of PSC.
Disease extent before the first surveillance colonoscopy was
defined as the maximum extent according to either the histology
or endoscopy reports. In UC and IBD-unclassified, disease extent
was defined as either left-sided or extensive (inflammation distal
or proximal to the splenic flexure, respectively). In patients with
Crohn’s colitis, involvement of $3 anatomical parts of the colon
was considered extensive disease, whereas involvement of 1 or 2
sections was considered limited diseases.
Neoplasia
For all suspected dysplastic lesions, the location and
endoscopic description was recorded. Based on the pathology
report, lesions were categorized as nondysplastic, indefinite for
dysplasia, low-grade dysplasia (LGD), high-grade dysplasia
(HGD), or CRC. Endoscopically visible lesions containing LGD
were subdivided in adenoma-like mass (discrete solitary sessile or
pedunculated polyps resembling sporadic adenomas and contain-
ing adenomatous tissue on histology) and non–adenoma-like mass
(all other endoscopic descriptions, i.e., plaque-like lesions,
irregular masses). Our primary endpoint was colitis-associated
neoplasia (CAN), defined as patients developing a non–adenoma-
like mass containing LGD, flat dysplasia (LGD or HGD), HGD,
or CRC.
Follow-up
Patients were followed up from the date of the first
surveillance colonoscopy until one of the following endpoints:
(1) last surveillance colonoscopy, (2) (sub)total colectomy, (3)
death, and (4) diagnosis of CAN.
Endoscopic risk factors were scored at each surveillance
colonoscopy during follow-up including extent and severity of
inflammation, presence of postinflammatory polyps, and stric-
tures. Severity of endoscopic and histologic inflammation was
scored as no, mild, moderate, or severe inflammation as specified
in the endoscopy and histology report. Patients were scored as
positive for each risk factor when this was present at one or more
surveillance colonoscopies during follow-up.
Surveillance Intervals
The enrolled patients were stratified in the risk groups as
specified in the new AGA and BSG guidelines to calculate the
colonoscopic workload of surveillance and to compare the yield
of CAN between the risk groups. Details about the risk factors
used by either guideline are provided in Figure 3.
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Statistical Analysis
Baseline patient and endoscopic characteristics during the
surveillance colonoscopies were analyzed using standard descrip-
tive statistics. The cumulative incidence of CAN was calculated
for the different risk strata according to the BSG and AGA
guidelines using Kaplan–Meier analysis and comparisons
between risk groups were made with log-rank testing. Patients
who did not develop CAN were censored at the moment of last
surveillance colonoscopy or colectomy. To test the discriminative
power of the risk groups of either guideline in identifying patients
with CAN, the C-statistic was calculated using Cox regression
analysis.
To calculate the colonoscopic workload of the BSG and
AGA guidelines, the contribution of each patient to the average
annual number of surveillance colonoscopies was calculated
based on the intervals described in either guideline. Univariate
and multivariate analysis was performed using Cox regression
analysis to identify predictors for the development of CAN. A
2-sided P value ,0.05 was considered statistically significant.
Data were analyzed using SPSS version 2.0 for Windows.
Ethical Considerations
This study was carried out with the approval of and in
accordance with the ethical guidelines of the medical ethical
committee of our institution.
RESULTS
Patients
Our search identified 4514 patients with a DTC code for
CD or UC. Surveillance was performed in 1018 patients (23%), of
whom 408 had Crohn’s colitis (40%), 573 had UC (56%), and 37
had indeterminate colitis (4%). Baseline characteristics of the
study population are shown in Table 1.
Surveillance Colonoscopies
In total, 2371 surveillance colonoscopies were performed
during the follow-up, with a median of 2 surveillance colonos-
copies per patient (range, 1–10). Bowel preparation was judged to
be adequate in 90% of surveillance colonoscopies, and the cecal
intubation rate was 97%. Chromoendoscopy was used in 53 sur-
veillance colonoscopies (2%), whereas random biopsies were
taken in the remaining 2318 colonoscopies (98%).
Active endoscopic inflammation was present in 777 (33%)
of surveillance colonoscopies and active histologic inflammation
in 947 (40%) surveillance colonoscopies (Table 2). Postinflam-
matory polyps were encountered in 506 surveillance colonoscop-
ies in 257 patients (25%).
Neoplasia During Follow-up
Neoplasia was detected during 1 or more of the follow-up
surveillance colonoscopies in 173 patients (15%) (Table 3). Based
on the endoscopy and histopathology reports, 64 (5%) patients
developed CAN during follow-up: 11 patients developed CRC,
6 patients HGD, 32 patients flat LGD and 15 patients a non–
adenoma-like mass with LGD (Table 3). The remaining 109 patients
developed either indefinite for dysplasia (11 patients) or an
adenoma-like mass containing LGD (98 patients). The cumulative
incidence of CAN by disease duration was 0.9% at 10 years, 6.2%
at 20 years, 16.9% at 30 years, and 35.3% at 40 years (Fig. 1).
Low-grade Dysplasia
Flat LGD was diagnosed in 36 patients, of whom 2 patients
progressed to HGD and 2 to CRC (Fig. 2). Flat LGD was unifocal
in 26 patients (72%) and located distally to the splenic flexure in
19 patients (53%).
A non–adenoma-like mass containing LGD was found in
16 patients (9 proximal to the splenic flexure, median size 16 mm
[range, 2–30]), which was treated by colectomy in 6 patients. In
none of these cases, HGD or CRC was detected in the colectomy
specimen. In 10 patients, the lesion was treated endoscopically. In
TABLE 1. Baseline Characteristics of Patients
Undergoing Surveillance
N (%)
No. of patients 1018 (100)
Male sex 491 (48)
Type of hospital
Referral center 737 (73)
General hospital 281 (27)
IBD diagnosis
UC 573 (56)
Distal splenic flexure 252 (44)
Proximal splenic flexure 309 (54)
Unknown 12 (2)
Crohn’s colitis 408 (40)
Segmental colitis ,50% 173 (42)
Segmental colitis .50% 216 (53)
Unknown 19 (5)
Indeterminate colitis 37 (4)
Segmental colitis ,50% 17 (46)
Segmental colitis .50% 19 (51)
Unknown 1 (3)
Age at first surveillance colonoscopy, yr (mean 6 SD) 46.7 (612.6)
Duration of IBD at first surveillance colonoscopy, yr
(mean 6 SD)
16.7 (68.3)
Concomitant diagnosis of PSC 64 (6)





Duration of follow-up, yr (median, range) 2.6 (0–12.5)
Partial or total colonic resection during follow-up 78 (8)
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one of these patients, who was operated on for refractory disease
3 years after removal of the non–adenoma-like mass, CRC was
unexpectedly diagnosed in the ileocecal resection specimen.
High-grade Dysplasia
HGD was diagnosed in 6 patients during the follow-up
(Fig. 2). Two patients developed HGD in an adenoma-like mass,
which was treated endoscopically in 1 patient and by colectomy in
the other patient. One patient developed flat HGD 1 year after
diagnosis of flat LGD, which was not treated by colectomy due to
advanced age. Two patients with HGD in a non–adenoma-like
mass were found to have synchronous multifocal flat LGD in
other segments of the colon. Both were treated by colectomy,
which confirmed the diagnoses of LGD and HGD, but revealed
no additional advanced neoplasia.
In 1 patient, HGD was diagnosed in biopsies surrounding
a non–adenoma-like mass containing LGD. The colectomy spec-
imen confirmed the presence of HGD and LGD with no additional
diagnosis of CRC.
Colorectal Cancer
A total of 12 CRC’s were diagnosed in 11 patients during
follow-up at a median age of 59 years (range, 39–69) (Fig. 2). In
5 patients, CRC was diagnosed without a previous diagnosis of
neoplasia, despite the fact that all patients underwent at least
1 surveillance colonoscopy before the CRC diagnosis with
a median interval between the last surveillance colonoscopy and
the CRC diagnosis of 26 (range, 20–47) months.
In 6 patients, dysplasia was detected during surveillance
colonoscopies before the diagnosis of CRC. The dysplasia
diagnosis was flat indefinite for dysplasia in 2 patients and
LGD in 4 patients (Fig. 2).
Surveillance Intervals According to the New
BSG Guidelines
Based on risk factors present during follow-up, surveillance
intervals were determined according to the AGA and BSG
guidelines in all 1018 patients. When applying the new BSG
guidelines, 421 patients (41%) were assigned to the low-risk
group (surveillance interval of 5 yr), 393 patients (39%) to the
intermediate-risk group (surveillance interval of 3 yr), and 204
patients (20%) to the high-risk group (annual surveillance
interval) (Fig. 3). CAN was detected in 15 low-risk patients
TABLE 2. Endoscopic Characteristics
N (%)
No. of colonoscopies 2371 (100)
Cecal intubation 2301 (97)
Suboptimal bowel preparation 244 (10)
No. of biopsies per colonoscopy (mean 6 SD)
Random biopsy protocol 27 (610)
Chromoendoscopy protocol 9 (65)
Endoscopic inflammation
No signs of previous or present inflammation 266 (11)
Quiescent disease 1328 (56)
Mild 621 (26)
Moderate to severe 156 (7)
Histologic inflammation
No signs of previous or present inflammation 110 (5)
Quiescent disease 1314 (55)
Mild 790 (33)
Moderate or severe 157 (7)
Postinflammatory polyps 506 (21)
Stricture
UC 10 (1)
Crohn’s colitis 65 (3)
TABLE 3. Neoplasia During Follow-up, Based on the
Maximal Grade of Dysplasia
Random Biopsy
Protocol (n ¼ 965)
Chromoendoscopy
Protocol (n ¼ 53)
Patients diagnosed with
neoplasia, n (%)
162 (17) 11 (21)
Indefinite for dysplasia, n (%) 11 (1) 0 (0)
LGD, n (%)
Adenoma-like mass 89 (9) 9 (17)
Flat dysplasia 31 (3) 2 (4)
Non–adenoma-like
mass
15 (1) 0 (0)
HGD, n (%) 6 (0.6) 0 (0)
CRC, n (%) 11 (1) 0 (0)
Dukes A 1 —
Dukes B 5 —
Dukes C 3 —
Dukes D 2 —
FIGURE 1. Kaplan–Meier curve showing the development of CAN by
disease duration. Vertical lines represent events of CAN defined as
non–adenoma-like LGD, HGD, or CRC.
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(3.6%; 14 LGD, 0 HGD, and 1 CRC), in 27 intermediate-risk
patients (6.9%; 21 LGD, 0 HGD, and 6 CRC), and in 22 high-risk
patients (10.8%; 12 LGD, 6 HGD, and 4 CRC). The 5-year cumu-
lative incidence of CAN was 5.6%, 7.2%, and 9.9% for the low-,
intermediate-, and high-risk groups, respectively (Fig. 4) (low versus
high risk P ¼ 0.07, low versus medium P ¼ 0.48, and medium
versus high P ¼ 0.33; log-rank test). If the primary endpoint was
limited to cases of HGD or CRC, the 5-year cumulative incidence
was 0.7%, 1.8%, and 4.3% for the low-, intermediate-, and high-risk
groups, respectively (Fig. 5) (low versus high risk P , 0.01, low
versus medium P ¼ 0.21, medium versus high P ¼ 0.09; log-rank
test). Using the new BSG intervals resulted in an average annual
workload of 420 surveillance colonoscopies, or 0.41 colonoscopies
per patient per year. When the 3 risk groups were entered in a Cox
regression analysis, the corresponding C-statistic was 0.55.
Surveillance Intervals According to the New
AGA Guidelines
In accordance with the new AGA guidelines, 954 patients
(94%) were assigned to the low-risk group and 64 patients (6%) to
the high-risk group (Fig. 3). CAN was detected in 51 low-risk
patients (5.3; 39 LGD, 2 HGD, and 10 CRC) and in 13 high-risk
patients (20.3%; 8 LGD, 4 HGD, and 1 CRC). The 5-year cumu-
lative incidence of CAN was 6.3% in the low-risk group and
18.7% in the high-risk group (P ¼ 0.02, log-rank) (Fig. 4). If
the primary endpoint was limited to cases of HGD or CRC, the
FIGURE 2. Flow chart showing the development of neoplasia during follow-up.
FIGURE 3. Flow chart showing the stratification of patients undergoing surveillance according to the AGA and BSG guidelines. FDR, first-degree
relative.
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5-year cumulative incidence was 1.7% in the low-risk group and
7.2% in the high-risk group (P ¼ 0.02, log-rank) (Fig. 5).
The average annual number of surveillance colonoscopies
when applying the AGA intervals was 541, or 0.53 per patient per
year, when a surveillance interval once every 2 years was used for
the low-risk group. When a surveillance interval of 3 years was
used for the low-risk group, the average annual number of
surveillance colonoscopies drops to 382 or 0.38 per patient per
year. Therefore, the colonoscopic workload when adopting the
BSG guidelines is 22% less than the workload associated with the
AGA guidelines if a surveillance interval once every 2 years for
the low-risk group is used. When the 2 risk groups were entered in
a Cox proportional hazards model, the corresponding C-statistic
was 0.57.
Factors Associated with the Development
of CAN
Univariate analysis showed that the development of CAN
was significantly associated with male sex (odds ratio [OR], 1.7),
a positive family history of CRC (OR, 3.2), PSC (OR, 2.6), the
presence of strictures in patients with UC (OR, 4.5), and the
absence of histologic inflammation (OR, 0.6). After multivariate
analysis the factors PSC, family history of CRC, the absence of
histological inflammation and the presence of strictures in patients
with UC remained significantly associated with the development
of CAN (Table 4).
DISCUSSION
The aim of this retrospective study was to assess whether
the risk-stratified approaches of the updated AGA or BSG
guidelines for surveillance were more effective in terms of
colonoscopic workload and neoplasia yield. The new BSG
guidelines were found to only moderately discriminate between
the 3 risk groups with regard to the overall incidence of CAN
(3.6%, 6.9%, and 10.8% for the low-, intermediate-, and high-risk
groups, respectively). In contrast, the overall yield of CAN in the
low-risk group of the AGA guidelines was 5.3%, which was
significantly lower than the 20.3% for the high-risk group.
However, if you compare the predictive power of the risk groups
of either guideline using the C-statistic, both guidelines show
a similar poor discriminative power with values of 0.55 (BSG)
and 0.57 (AGA).
The differences in neoplasia yield come with a cost;
however, the risk of CAN in the low-risk group of the AGA
guidelines is higher than in the low-risk group of the BSG
guidelines (5.3% versus 3.6%). Whether the shorter surveillance
intervals of the AGA guideline protect these low-risk patients
from developing advanced neoplasia remains to be studied.
A potential advantage of risk stratification is the avoidance
of unnecessary colonoscopies. We found that implementation of
the BSG guidelines reduced the colonoscopic workload by 22%
as compared with the AGA guidelines. The authors of the new
BSG guidelines estimated the percentages of patients in each risk
FIGURE 4. Kaplan–Meier curve comparing the cumulative incidence of CAN between the risk groups of the BSG guideline (left) and the AGA
guideline (right). CAN is defined as non–adenoma-like LGD, HGD or CRC. Low risk versus high risk, P ¼ 0.07; Low versus intermediate, P ¼ 0.48;
intermediate versus high, P ¼ 0.33 (BSG guideline). Low risk versus high risk, P ¼ 0.02 (AGA guideline).
FIGURE 5. Kaplan–Meier curve comparing the cumulative incidence of HGD or CRC between the risk groups of the BSG guideline (left) and the
AGA guideline (right). Low-risk versus high-risk, P , 0.01; low versus intermediate, P ¼ 0.21; intermediate versus high, P ¼ 0.09 (BSG guideline).
Low risk versus high risk, P ¼ 0.02 (AGA guideline).
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group to be 15%, 30%, and 55% for the high-, intermediate-, and
low-risk groups, which is more or less in line with our results (20%,
39%, and 41%, respectively).7 One other study also reported that
the colonoscopic workload could be reduced by 15% using the new
BSG guidelines.9
However, these differences in colonoscopic workload
critically depend on arbitrarily chosen surveillance intervals. For
example, if a surveillance interval of 3 years would be applied to
the lower risk group of the AGA guidelines, the colonoscopic
workload would be 9% lower than the workload associated with
the BSG guidelines. Because no prospective data are available
comparing different surveillance intervals in colitis patients,
stratification as defined by the AGA guidelines with a surveillance
interval of 3 years for the low-risk group might offer the best
compromise with regard to the identification of CAN and the
reduction of colonoscopic workload.
Some established risk factors for colitis-associated CRC
implemented in the new AGA and BSG guidelines were
confirmed in our study. We found a 2.5-fold higher risk of
developing CAN in patients with a concomitant diagnosis of PSC,
which is in line with earlier reports.10,11 Patients with a first-degree
relative diagnosed with CRC had a higher risk as well, although
conflicting data in literature exist on this issue.12–15 We also con-
firmed that the absence of histologic signs of inflammation is
associated with a reduced risk of developing CRC.16 Several
studies have suggested that endoscopic features reflecting long-
standing severe inflammation such as postinflammatory polyps,
strictures, and active inflammation during surveillance can predict
the risk of subsequent development of neoplasia as well.14,17
Apart from the association between strictures in patients with
UC and neoplasia development, we could not confirm this. Stric-
tures in patients with UC are rare, but if present carry a high risk
of CRC.18,19 In our study, 9 patients with UC developed a stricture,
of which 2 developed CRC and 1 HGD, underscoring the need for
close surveillance or even colectomy in these patients. The mod-
erate performance of the BSG guidelines in identifying patients at
higher risk of CAN in our study can partially be attributed to its
strong dependence on endoscopic parameters. Based on our re-
sults, it seems questionable whether these factors should be used
to stratify patients for surveillance. Our study has several limita-
tions. Due to the retrospective design, patients in this study were
not screened in accordance with the updated intervals of the BSG
and AGA guidelines, and therefore the longer intervals of 3 and
5 years were not yet implemented. Although the incidence of
CAN was used as an endpoint to compare the different risk strata,
the potential drawbacks of a longer surveillance interval such as
the occurrence of more advanced neoplasia and interval carcino-
mas could not be assessed. Furthermore, the presence of known
risk factors for IBD-associated CRC such as a diagnosis of PSC or
the presence of postinflammatory polyps could have triggered an
increased awareness from the endoscopists, which could have
overestimated the incidence of CAN in these high-risk patients.
However, because we found only a moderate discriminative
power for the risk factors used in both guidelines, the presence
of this bias would only underscore our results.
Despite the fact that more than 1000 patients were included,
only 11 patients developed CRC (during 3172 patient-years of
follow-up). For that reason, we also included colitis-associated
LGD and HGD in a composite endpoint. Especially for lesions
with LGD, there is no consensus on how colitis-associated lesions
can be distinguished from sporadic adenomas, which could have
introduced bias. Furthermore, there is considerable interobserver
variability among pathologists for the diagnosis of LGD in the
setting of colitis, which could have introduced bias as well
because the pathology slides were not reviewed by an expert
panel.20 We aimed to minimize the interference of sporadic ade-
nomas and carcinomas by reviewing the endoscopic and histo-
logic description of each lesion containing dysplasia and
excluding all discrete sessile or pedunculated lesions containing
adenomatous tissue.
Both the updated AGA and BSG guidelines advocate the
use of chromoendoscopy with targeted biopsies because of
a superior neoplasia yield over random biopsies.21 Because most
colonoscopies in this study were performed before the publication
of these updated guidelines, only 53 colonoscopies (2%) were
performed using chromoendoscopy. Whether chromoendoscopy
performs better among high-risk patients as compared with the
intermediate- or low-risk patients is currently unknown, and there-
fore we refrain from speculation how chromoendoscopy would
have affected the results if used in the majority of patients.
Patients were stratified for their next surveillance interval, but
we were unable to incorporate changing surveillance intervals
during follow-up due to transient risk factors, particularly
TABLE 4. Cox Proportional Hazard Analysis of the
Association Between Several Known Risk Factors and





Male sex 1.7 (1.0–2.9) 1.4 (0.80–2.5)
UC (versus CD) 1.3 (0.8–2.2) 1.1 (0.6–2.1)
Extensive colitis 1.0 (0.6–1.8) 0.9 (0.5–1.9)
Endoscopic inflammation
No inflammation 0.8 (0.5–1.3) 0.8 (0.5–1.5)
Mild 0.7 (0.4–1.1) 0.6 (0.3–1.1)
Moderate/severe 1.2 (0.6–2.3) 0.9 (0.4–2.1)
Histologic inflammation
No inflammation 0.6 (0.3–1.0) 0.4 (0.2–0.8)
Mild 0.8 (0.5–1.3) 0.6 (0.3–1.1)
Moderate/severe 1.2 (0.6–2.1) 1.1 (0.5–2.4)
Stricture (patients with UC) 4.5 (1.4–14.4) 3.8 (1.1–13.3)
First-degree relative with CRC
diagnosis
3.2 (1.4–7.6) 3.9 (1.6–9.5)
Postinflammatory polyps 1.1 (0.7–1.9) 1.1 (0.6–2.1)
History of PSC 2.6 (1.4–4.7) 2.5 (1.2–5.0)
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inflammation. We believe, however, that although some patients
will be assigned to other surveillance intervals because of this, the
total number of patients with active inflammation will remain
approximately stable over time, and therefore the influence on
colonoscopic workload is probably small.
Due to the retrospective design, we relied on the endoscopy
reports to determine whether endoscopic risk factors such as
active inflammation or postinflammatory polyps were present.
The fact that endoscopists might interpret the endoscopic findings
differently could have resulted in an overestimation or underes-
timation of the presence of these factors. Furthermore, well-
defined and validated endoscopic and histologic scores reliably
reflecting the severity of inflammation were not used.
We included both patients with UC and Crohn’s colitis in
this study. Although several studies indicate that the risk of CRC
is similar when disease extent and duration are comparable, most
studies reporting on risk factors for developing CRC only include
patients with UC.14,17,22 It might well be that risk factors for CRC
are different in patients with Crohn’s colitis, which could have
affected our results. However, in the univariate and multivariate
analysis of individual risk factors, the type of IBD was not asso-
ciated with the development of CAN.
In conclusion, this study shows the clinical consequences if
the new AGA or BSG guidelines are applied to a large cohort of
patients with IBD undergoing surveillance. Although the longer
surveillance intervals of the new BSG guidelines reduce the
colonoscopic workload considerably compared with the AGA
guidelines, the risk strata as defined in the AGA guidelines are
superior in distinguishing patients at high and low risk of CAN.
Furthermore, if a 3-year surveillance interval is applied to the
lower risk group of the AGA guidelines, the workload is 9%
lower compared with the BSG guidelines. Whether the lower
incidence of CAN in the low-risk groups of both guidelines
justifies longer surveillance intervals is presently unknown and
should be the focus of future studies.
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